Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Evolus (NASDAQ: EOLS) has announced the grant of 15,332 restricted stock units (RSUs) to 6 newly hired non-executive employees. The grants were approved by the company's compensation committee under the 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of January 7, 2025. The RSUs will vest at a rate of 25% annually on each anniversary of the vesting commencement date. The grants serve as an inducement for employment and comply with Nasdaq Listing Rule 5635(c)(4). Recipients must maintain continuous employment to meet vesting requirements.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under the Evolus’ 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of January 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed on each vesting date.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^®(prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse^™, and the exclusive distributor in Europe of Estyme^®, a line of unique injectable hyaluronic acid (HA) gels. These injectable HA gels are currently in the late stages of the regulatory approval process, with plans, upon approval, for a launch starting in 2025.

Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau^® and Nuceiva^®, are registered trademarks and Evolysse^™ is a trademark of Evolus, Inc.
Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
Estyme^® is a trademark of Symatese Aesthetics S.A.S.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250117719857/en/

Evolus Contacts:

Investors:

Nareg Sagherian

Vice President, Head of Global Investor Relations and Corporate Communications

Tel: 248-202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

Source: Evolus

FAQ

How many RSUs did Evolus (EOLS) grant to new employees in January 2025?

Evolus granted 15,332 restricted stock units (RSUs) to 6 newly hired non-executive employees.

What is the vesting schedule for Evolus (EOLS) January 2025 RSU grants?

The RSUs vest 25% annually on each anniversary of the vesting commencement date of January 7, 2025.

Under which plan were the Evolus (EOLS) January 2025 RSU grants approved?

The RSU grants were approved under Evolus' 2023 Inducement Incentive Plan.

What are the requirements for Evolus (EOLS) employees to maintain their RSU grants?

Employees must remain continuously employed with Evolus on each vesting date to maintain their RSU grants.